2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5548 Pregnancy and assisted reproductive technology related outcomes in patients with BCR-ABL1 negative myeloproliferative neoplasms

Yamna Jadoon, MD, MBBS, Shiyuan Liu, MD2, Patricia A. Cornett, MD3, Kelly Schoenbeck, MD4
1 University of California San Francisco, San Francisco, California, United States
2 University of California San Francisco, San Francisco, California, United States
3 University of California San Francisco, San Francisco, California, United States
4 University of California San Francisco, San Francisco, California, United States

Background:  Patients with BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are primarily diagnosed during their 7th decade, however, 15–20% of patients are diagnosed during their reproductive years. Despite increased maternal and fetal risks during pregnancy, there is limited data to guide management in this population, and even less during the use of assisted reproduction technology (ART). The primary aim for this study was to define the characteristics, management, and outcomes of patients with MPNs related to pregnancy or ART in our health care system.

Methods: We performed a multi-site, retrospective cohort study of MPN patients at 5 sites in the UCSF Health System between January 2012 and March 2026. Patients were identified by ICD-10 codes and chart abstraction. Reproductive age was defined as age ≤50 years. High risk pregnancy was defined as prior MPN-related thrombosis, hemorrhage, or previous pregnancy complications (defined by Lishner, et al). Problem and medication lists were reviewed for diagnoses and medications, and provider notes for clinical outcomes. Descriptive statistics were used to summarize the data.

Results: Of 1260 MPN patients, 655 (52%) were women and 27.8% (n=182/655) were of reproductive age at the time of MPN diagnosis. Pregnancy and ART outcomes were identified in 32 patients (17.6%; n=32/182), with 81.25% (n=26/32) having pregnancies and 18.8% (n=6/32) unable to conceive. The most frequently cited race/ethnicities were Caucasian (62.5%; n=20/32), Asian (12.5%; n=4/32), Black (9.4%; n=3/32), and Hispanic (9.4%; n=3/32).  The mean age at MPN diagnosis was 31.4 years (range 19–39) and mean age at conception was 35.0 years (range 19–43). The mean number of pregnancies was 1.8 (range 1–5). Patients had essential thrombocythemia (ET; 62.5%; n=20/32), MPN-U (18.8%; n=6/32), polycythemia vera (PV; 15.6%; n=5/32), ET vs pre-fibrotic myelofibrosis (3.1%; n=1/32), and post-ET myelofibrosis (3.1%; n=1/32). Driver mutations included JAK2 V617F (75%; n=24/32), CALR (12.5%; n=4/32), triple-negative (9.4%; n=3/32), and JAK2 V617F/CALR (3.1%; n=1/32).

In vitro fertilization (IVF) was used by 18.8% (n=6/32), and 5 (83.3%) patients became pregnant. Of 17 fetal embryo transfers (FET), 9 resulted in pregnancy. Mean egg retrievals were 1.2 (range 1–10), and mean embryo transfers were 3.4 (range 1–5). During ART, 2 received LMWH peri-egg retrieval and post-FET, and 3 with low dose aspirin.

A total of 50 pregnancies were identified among 26 patients, including 48 singleton and 2 twin pregnancies. Patients with standard risk pregnancies were treated with aspirin 81 mg (n=30) or 162 mg (n=5); 2 were treated with aspirin and prophylactic LMWH. Six pregnancies were considered high risk and managed with therapeutic LMWH (n=1), or in combination with aspirin 81 mg (n=2) or 162 mg (n=1). Cytoreduction was offered in 1 case and declined due to patient preference.

Pregnancy outcomes included 28 term deliveries (56%), 12 miscarriages (24%), 3 preterm deliveries (6%), 2 elective terminations (4%), 1 stillbirth (2%) and 1 ectopic pregnancy (2%); 2 pregnancies (4.4%) were ongoing. Most were delivered via spontaneous vaginal delivery (SVD) (n=22). Maternal complications included antepartum hemorrhage (n=2), postpartum hemorrhage (n=4), pre-eclampsia (n=2), placental abruption (n=1). Fetal complications included fetal intolerance of labor (n=5), intrauterine growth restriction (n=2), macrosomia (n=1), vanishing twin syndrome (n=1), and respiratory distress syndrome (n=1). The 6 high risk pregnancies resulted in 4 viable pregnancies (3 term and 1 preterm; 3 c-sections and 1 SVD) and 2 non-viable pregnancies (1 ectopic, 1 miscarriage). Complications included fetal intolerance of labor (n=3), hemorrhage (n=3), pre-eclampsia (n=1), and placental abruption (n=1).

Conclusion: Our study supports that successful ART and pregnancy outcomes are achievable in patients with MPNs through individualized risk assessment and coordinated hematologic and obstetric care. Limitations include small number of patients utilizing ART and the lack of cytoreduction used in high risk pregnancies. We did find nearly one-fifth of our patients were unable to conceive, and nearly one-third experienced miscarriages/stillbirth, a rate higher than found in other MPN studies. Future directions include exploring associations with infertility and early pregnancy loss in our cohort.

Yamna Jadoon, MD, MBBS: No relevant conflicts of interest to declare.